A COST/UTILITY DECISION ANALYSIS OF RITUXIMAB VS ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF THERAPY. ARGENTINEAN COST AND PREFERENCES

J.P. Solé, M. Manzotti, M.C. Mestroni, D.R. Millan, J.C. BarreiraAutoimmune diseases, Roche S.A.Q. e I; Internal Medicine, Deutsches Hospital; Internal Medicine, Hospital Fernandez; Clinical Reserch, Medeos; Rheumatology, British Hospital, Buenos Aires, ArgentinaCitation: Ann Rheum Dis, volume 67, supplement II, year 2008, page 610Session: RA – Other biologic treatment